Format

Send to

Choose Destination
Early Hum Dev. 2017 Oct;113:10-17. doi: 10.1016/j.earlhumdev.2017.07.011. Epub 2017 Jul 8.

Efficacy of pharmacologic closure of patent ductus arteriosus in small-for-gestational-age extremely preterm infants.

Author information

1
Department of Epidemiology & Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
2
Biostatistics and Epidemiology Division, RTI International, Research Triangle Park, NC, USA.
3
Department of Pediatrics, University of Iowa, Iowa City, IA, USA. Electronic address: edward-bell@uiowa.edu.
4
Department of Pediatrics, University of Iowa, Iowa City, IA, USA.
5
Department of Pediatrics, Mayo Clinic, Rochester, MN, USA.
6
Dean's Office, University of Texas Health Science Center at Houston, Houston, TX, USA.
7
Department of Pediatrics, Women & Infants Hospital, Brown University, Providence, RI, USA.
8
Social, Statistical, and Environmental Sciences Unit, RTI International, Rockville, MD, USA.
9
Department of Pediatrics, Wayne State University, Detroit, MI, USA.
10
Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA.
11
Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
12
Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA.

Abstract

BACKGROUND:

Optimal management of the patent ductus arteriosus (PDA) in preterm infants remains controversial. Therefore, studies identifying infants who are most likely to benefit from PDA treatment are needed.

AIM:

We sought to examine if significant intrauterine growth restriction, defined by birth weight z-score, reduces the efficacy of PDA closure with indomethacin or ibuprofen and thereby increases the need for surgical closure of PDA after pharmacologic treatment.

STUDY DESIGN, SUBJECTS, AND OUTCOME MEASURES:

We studied infants 23-28weeks' gestation born 2006-2013 at NICHD Neonatal Research Network centers. We examined the responses to PDA treatment with indomethacin and/or ibuprofen and whether the PDA was subsequently closed surgically. Logistic regression generated adjusted odds ratios (ORs) for the associations between the z-score groups (<-2, -2 to -0.5, and >-0.5) and PDA surgery following pharmacologic treatment.

RESULTS:

5606 infants were diagnosed with PDA; 3587 (64.0%) received indomethacin or ibuprofen or both, and 909 (25.3%) underwent PDA surgery. Mothers of infants with PDA non-closure were less likely to have hypertension (19% vs. 28%). Infants with non-closure were more likely to be female (53% vs. 49%), have lower gestational age and birth weight and to develop sepsis (42% vs. 31%). Compared to infants with z-score>-0.5, PDA surgery was increased among infants with z-score -2 to -0.5 (OR=1.23; 95% CI 1.02-1.47) but not among infants with z-score<-2.

CONCLUSION:

Infants with birth weight z-score -2 to -0.5 are more likely than normally grown infants to require PDA surgery following pharmacologic treatment.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00063063 NCT00009633.

KEYWORDS:

Ibuprofen; Indomethacin; Morbidity; Mortality; Premature infants

PMID:
28697406
PMCID:
PMC5654678
DOI:
10.1016/j.earlhumdev.2017.07.011
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center